3. Have had documented disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST; Therasse et al. 2000) within 3 months after receiving FOLFOX plus bevacizumab as first-line therapy for locally advanced or metastatic disease, or within 6 months after receiving FOLFOX with or without bevacizumab in the adjuvant setting.